These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 21968130)

  • 61. Use of bortezomib to treat anti-HLA antibodies in renal transplant patients: a single-center experience.
    Cicora F; Paz M; Mos F; Roberti J
    Transpl Immunol; 2013 Dec; 29(1-4):7-10. PubMed ID: 23994721
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Rituximab and intravenous immune globulin for desensitization during renal transplantation.
    Vo AA; Lukovsky M; Toyoda M; Wang J; Reinsmoen NL; Lai CH; Peng A; Villicana R; Jordan SC
    N Engl J Med; 2008 Jul; 359(3):242-51. PubMed ID: 18635429
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Bortezomib-based treatment of antibody mediated rejection in pancreas allograft recipients.
    Govil A; Walsh RC; Tevar A; Alloway R; Roy-Chaudhury P; Mogilishetty G; Wall GE; Brailey P; Girnita A; Woodle ES
    Clin Transpl; 2009; ():443-53. PubMed ID: 20524313
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation.
    Vo AA; Peng A; Toyoda M; Kahwaji J; Cao K; Lai CH; Reinsmoen NL; Villicana R; Jordan SC
    Transplantation; 2010 May; 89(9):1095-102. PubMed ID: 20110854
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
    Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
    Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Prospective iterative trial of proteasome inhibitor-based desensitization.
    Woodle ES; Shields AR; Ejaz NS; Sadaka B; Girnita A; Walsh RC; Alloway RR; Brailey P; Cardi MA; Abu Jawdeh BG; Roy-Chaudhury P; Govil A; Mogilishetty G
    Am J Transplant; 2015 Jan; 15(1):101-18. PubMed ID: 25534446
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Desensitization for sensitized patients awaiting heart transplant.
    Byku M; Chang PP
    Curr Opin Organ Transplant; 2019 Jun; 24(3):233-238. PubMed ID: 31090629
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates.
    Wahrmann M; Haidinger M; Körmöczi GF; Weichhart T; Säemann MD; Geyeregger R; Kikić Z; Prikoszovich T; Drach J; Böhmig GA
    Transplantation; 2010 Jun; 89(11):1385-90. PubMed ID: 20335829
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Bortezomib rescue in refractory acute humoral rejection--report of a case.
    Shapiro R; Basu A; Zeevi A; Lunz J; Mapara M; Randhawa P; Morgan C; Tan HP; Sharma V
    Clin Transpl; 2009; ():431-2. PubMed ID: 20524310
    [No Abstract]   [Full Text] [Related]  

  • 70. The effectiveness of the combination of rituximab and high-dose immunoglobulin in the immunomodulation of sensitized kidney transplant candidates.
    Taber T; Mujtaba MA; Goggins W; Higgins N; Sharfuddin A; Yaqub MS; Mishler D; Book B; Chen J; Lobashevsky A
    Clin Transplant; 2013; 27(4):E375-82. PubMed ID: 23721524
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The state of therapy for removal of alloantibody producing plasma cells in transplantation.
    Everly MJ; Terasaki PI
    Semin Immunol; 2012 Apr; 24(2):143-7. PubMed ID: 22153981
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Bortezomib in kidney transplant desensitization: a case report.
    Raghavan R; Jeroudi A; Achkar K; Suki W; Gaber AO; Knight R; Land G; Dilioglou S; Patel S; Abdellatif A
    Clin Transpl; 2009; ():339-42. PubMed ID: 20524295
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation.
    Sureshkumar KK; Hussain SM; Marcus RJ; Ko TY; Khan AS; Tom K; Vivas CA; Parris G; Jasnosz KM; Thai NL
    Clin Nephrol; 2012 Mar; 77(3):246-53. PubMed ID: 22377258
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Sensitisation and post-transplant course after the implantation of ventricular assist device.
    Malickaite R; Rucinskas K; Staneviciene A; Miniauskas S; Maneikiene V; Zuoziene G; Sirvydis V
    Interact Cardiovasc Thorac Surg; 2009 Mar; 8(3):339-42; discussion 342-3. PubMed ID: 19098066
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Bortezomib in ABO-incompatible kidney transplant desensitization: a case report.
    Wong NL; O'Connell P; Chapman JR; Nankivell B; Kable K; Webster AC; Wong G
    Nephrology (Carlton); 2015 Mar; 20 Suppl 1():22-4. PubMed ID: 25807854
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Monitoring and treating posttransplant human leukocyte antigen antibodies.
    Everly MJ; Terasaki PI
    Hum Immunol; 2009 Aug; 70(8):655-9. PubMed ID: 19375466
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Transplantation of high panel-reactive antibody left ventricular assist device patients without crossmatch using on-bypass pheresis and alemtuzumab.
    Lick SD; Beckles DL; Piovesana G; Vaidya S; Indrikovs A; Barbagelata NA; Valentine V
    Ann Thorac Surg; 2011 Oct; 92(4):1428-34. PubMed ID: 21855854
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effectiveness of rituximab and intravenous immunoglobulin therapy in renal transplant recipients with chronic active antibody-mediated rejection.
    Hong YA; Kim HG; Choi SR; Sun IO; Park HS; Chung BH; Choi BS; Park CW; Kim YS; Yang CW
    Transplant Proc; 2012 Jan; 44(1):182-4. PubMed ID: 22310610
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pre- and posttransplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival.
    Ho EK; Vlad G; Vasilescu ER; de la Torre L; Colovai AI; Burke E; Deng M; Schwartz J; Marboe C; Mancini D; Opelz G; Suciu-Foca N
    Hum Immunol; 2011 Jan; 72(1):5-10. PubMed ID: 20971146
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Prevention and treatment of alloantibody-mediated kidney transplant rejection.
    Bartel G; Schwaiger E; Böhmig GA
    Transpl Int; 2011 Dec; 24(12):1142-55. PubMed ID: 21831227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.